IL13RA2 and glioblastoma: Encouraged by initial studies proving the safe application of engineered first generation CAR-T cells targeting IL-13Rα2 [93], which is co-expressed on bulk GBM cells and glioma stem cells [94], investigators from the City of Hope have registered a follow-up trial to analyze the efficacy of 4-1BB-co-stimulated second-generation IL-13Rα2-specific CAR-T cells in relapsing and refractory GBM (NCT02208362, NCT00730613).